Caris is a precision medicine company that pioneered the introduction of precision medicine to cancer care and built an industry around personalized patient diagnostics. The company leverages cutting-edge molecular science and artificial intelligence to provide cancer patients with diagnostic answers tailored to their unique DNA profiles. A key product is MI Clarity, an AI-powered prognostic assay designed to assess distant recurrence risk in postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer. Caris partners with oncologists, surgeons, pathologists, and healthcare systems to integrate these molecular diagnostics into clinical workflows, aiming to optimize patient care through risk stratification and reduce both overtreatment and undertreatment. Beyond cancer, the company is expanding its mission to improve the human condition across multiple diseases through innovation and precision healthcare.
Beta · Sourced from candidate reports
Be the first to share your experience with Caris MPI, Inc..
Your reply helps other candidates know what to expect.
